ER2001
/ ExoRNA Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
January 16, 2026
The Safety and Tolerability Study With ER2001 Intravenous Injection Repetitive Treatment in Adults With Early Manifest Huntington's Disease.
(clinicaltrials.gov)
- P1 | N=9 | Active, not recruiting | Sponsor: ExoRNA Bioscience
New P1 trial • Genetic Disorders • Huntington's Disease • Movement Disorders
January 15, 2026
A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.
(clinicaltrials.gov)
- P1/2 | N=27 | Active, not recruiting | Sponsor: ExoRNA Bioscience
New P1/2 trial • Genetic Disorders • Huntington's Disease • Movement Disorders
December 20, 2025
The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease
(clinicaltrials.gov)
- P1 | N=10 | Completed | Sponsor: ExoRNA Bioscience | Recruiting ➔ Completed | N=15 ➔ 10 | Trial completion date: Dec 2024 ➔ Sep 2025 | Trial primary completion date: Oct 2024 ➔ Jan 2025
Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Huntington's Disease • Movement Disorders
November 05, 2024
First-in-Man Clinical Pilot Study Showing the Safety and Tolerability of Intravenous Injection of ER2001 (a Self-Assembled HTT-Specific siRNA) in Patients with Early Manifest HD
(HSG 2024)
- "Intravenous injection of ER2001 is safe and feasible in patients with early manifest HD, thus warranting further evaluation in randomized clinical trials."
Clinical
1 to 4
Of
4
Go to page
1